Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritis

Lupus

Volumn 19, Issue 5, 2010, Pages 628-633

  Walsh, M ^a,b   Jayne, D ^b   Moist, L ^c   Tonelli, M ^d   Pannu, N ^d   Manns, B ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Glucocorticoids; Nephritis; Renal lupus

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETIDRONIC ACID; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; STEROID;

ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TOLERANCE; DRUG WITHDRAWAL; HEMATURIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL EXPERT; PHYSICIAN; PRIORITY JOURNAL; PROFESSIONAL COMPETENCE; PROTEINURIA; QUESTIONNAIRE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; GLUCOCORTICOIDS; HUMANS; LUPUS NEPHRITIS; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES;

EID: 77950224795     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309356292     Document Type: Article

References (31)

1. Baldwin DS, Lowenstein J., Rothfield NF, Gallo G., McCluskey RT The clinical course of the proliferative and membranous forms of lupus nephritis. Ann Intern Med 1970 ; 73: 929-942.
2. Nossent JC, Bronsveld W., Swaak AJ Systemic lupus erythematosus. III. Observations on clinical renal involvement and follow up of renal function: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 1989 ; 48: 810-816. (Pubitemid 19258533)
3. Illei GG, Takada K., Parkin D., et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002 ; 46: 995-1002. (Pubitemid 34303812)
4. Zonana-Nacach A., Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000 ; 43: 1801-1808. (Pubitemid 30642567)
5. Gourley MF, Austin HA III, Scott D., et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996 ; 125: 549-557. (Pubitemid 126450087)
6. Yee CS, Gordon C., Dostal C., et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 2004 ; 63: 525-529. (Pubitemid 38530195)
7. Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986 ; 314: 614-619. (Pubitemid 16132725)
8. Bertsias G., Ioannidis JP, Boletis J., et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008 ; 67: 195-205. (Pubitemid 351183308)
9. Hoes JN, Jacobs JWG, Boers M., et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007 ; 66: 1560-1567. (Pubitemid 350205441)
10. Moroni G., Quaglini S., Maccario M., Banfi G., Ponticelli C. Nephritic flares are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996 ; 50: 2047-2053. (Pubitemid 26417549)
11. Ginzler EM, Aranow C. Prevention and treatment of adverse effects of corticosteroids in systemic lupus erythematosus. Baillieres Clin Rheumatol 1998 ; 12: 495-510. (Pubitemid 28488245)
12. Davis JM III, Maradit KH, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: A population-based cohort study. Arthritis Rheum 2007 ; 56: 820-830. (Pubitemid 46399429)
13. Eastell R., Devogelaer JP, Peel NF, et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 2000 ; 11: 331-337. (Pubitemid 30417186)
14. McDougall R., Sibley J., Haga M., Russell A. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 1994 ; 21: 1207-1213. (Pubitemid 24234653)
15. Mitchell DM, Spitz PW, Young DY, et al. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986 ; 29: 706-714. (Pubitemid 16094147)
16. Roger L. Serious adverse events with low-dose, long-term corticosteroid therapy in rheumatoid arthritis. Am J Med 1995 ; 99: 692-694. (Pubitemid 26006456)
17. Saag KG, Koehnke R., Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994 ; 96: 115-123. (Pubitemid 24070529)
18. Wolfe F., Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994 ; 37: 481-494. (Pubitemid 24115934)
19. Manzi S., Selzer F., Sutton-Tyrrell K., et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999 ; 42: 51-60. (Pubitemid 29042570)
20. Lima DS, Sato EI, Lima VC, et al. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 2002 ; 29: 292-297. (Pubitemid 34118776)
21. Asanuma Y., Oeser A., Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003 ; 349: 2407-2415. (Pubitemid 37542989)
22. Roman MJ, Shanker BA, Davis A., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003 ; 349: 2399-2406. (Pubitemid 37542988)
23. Asanuma Y., Chung CP, Oeser A., et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006 ; 33: 539-545. (Pubitemid 43334577)
24. Richter B., Neises G., Clar C. Glucocorticoid withdrawal schemes in chronic medical disorders. A systematic review. Endocrinol Metab Clin North Am 2002 ; 31: 751-778.
25. Walsh M., Merkel PA, Mahr A., Jayne D. A systematic review and meta-analysis of relapses in ANCA-Associated Vasculitis (AAV): what is the effect of low-dose corticosteroids? J Am Soc Nephrol 2007 ; 19: PO919.
26. Kirwan JR The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995 ; 333: 142-146.
27. da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006 ; 65: 285-293.
28. Capell HA, Madhok R., Hunter JA, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 2004 ; 63: 797-803. (Pubitemid 38850450)
29. Hricik DE, OToole MA, Schulak JA, Herson J. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol 1993 ; 4: 1300-1305.
30. Kasiske BL, Chakkera HA, Louis TA, Ma JZ A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000 ; 11: 1910-1917.
31. Pascual J., Quereda C., Zamora J., Hernandez D. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 2004 ; 78: 1548-1556. (Pubitemid 39552943)